Literature DB >> 26521776

Postoperative Approach for Crohn's Disease: The Right Therapy to the Right Patient.

Paulo Gustavo Kotze1, Takayuki Yamamoto2, Aderson O M C Damiao3.   

Abstract

BACKGROUND: Recurrence is a common event after surgical resections secondary to Crohn's disease (CD). Endoscopic signs of inflammation, defined as postoperative endoscopic recurrence (PER) occur in up to 90% of the patients after one year. PER precedes clinical recurrence and further need for reoperations due to consequent bowel damage. Therefore, controlling inflammation after surgery in a preventive way is essential for disease control.
OBJECTIVE: to review data regarding PER in CD, and demonstrate algorithms for its management after surgery.
RESULTS: There is no fixed strategy to prevent recurrence after surgery in CD. There are several risk factors that must be taken into consideration to guide physicians to choose the best therapeutic agents and strategies in this scenario. In this review, the authors describe in details the stratification based on risk factors, the therapeutic agents mostly used to prevent recurrence and discuss the several options for the postoperative management in CD.
CONCLUSIONS: No fixed strategy is recommended after surgical resections in CD. Thus, the need for a personalized approach for each patient is emphasized, in accordance with several conditions and variables. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Crohn´s disease; inflammation; postoperative care; postoperative endoscopic recurrence; recurrence; therapy.

Mesh:

Year:  2018        PMID: 26521776     DOI: 10.2174/1389450116666151102094922

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  1 in total

1.  The old versus the new: which do you keep in postoperative Crohn's disease?

Authors:  Paulo Gustavo Kotze; Christopher Ma; Miguel Regueiro; Remo Panaccione
Journal:  Intest Res       Date:  2018-04-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.